文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-FDG PET生物标志物预测转移性黑色素瘤抗PD1疗效与预后

Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-07-25

回顾性纳入两个中心55例抗PD1治疗前接受18F-FDG PET/CT的转移性黑色素瘤患者,评估脾与骨髓代谢等参数与生存和缓解的关系。中位随访20.7个月,TMTV、SLR和BLR升高与生存缩短相关;多变量分析中TMTV与PFS和OS、BLR与OS仍显著。低TMTV和TLG与最佳总体缓解相关,骨髓葡萄糖代谢升高与调节性T细胞标志物转录组相关。

要点

  • 治疗前TMTV>25cm3与更短PFS和OS独立相关。
  • 治疗前BLR>0.79与更短OS独立相关。
  • 低TMTV和TLG与最佳总体缓解相关。

核心结论

  • 低肿瘤负荷与生存和客观缓解相关,而造血组织代谢与生存呈负相关。
  • 这些生物标志物需进一步评估以用于临床。

研究设计与样本

  • 回顾性研究,纳入两个中心55例抗PD1治疗前接受18F-FDG PET/CT的转移性黑色素瘤患者。
  • 提取SUVmax、SUVmean、HISUV、TMTV、TLG、BLR和SLR,并以中位数二分。
  • 采用Cox模型评估生存关联,Wilcoxon检验评估缓解关联,Spearman相关评估转录组关联。

主要发现

  • 中位随访20.7个月,33例患者缓解,29例死亡。
  • 中位PFS为11.4个月(95%CI 2.7-20.2),中位OS为28.5个月(95%CI 13.4-43.8)。
  • TMTV>25cm3、SLR>0.77和BLR>0.79与更短生存相关。
  • 多变量分析中TMTV与PFS(HR 2.2,p=0.02)和OS(HR 2.5,p=0.02)显著相关,BLR与OS(HR 2.3,p=0.04)显著相关。
  • 低TMTV和TLG与最佳总体缓解相关(p=0.03)。

关键数值与推荐

  • TMTV以>25cm3为阈值与更短生存相关。
  • SLR以>0.77为阈值与更短生存相关。
  • BLR以>0.79为阈值与更短生存相关。

临床怎么用

  • 抗PD1治疗前18F-FDG PET/CT可评估肿瘤负荷(TMTV、TLG)和造血组织代谢(BLR、SLR)以辅助预后分层。
  • 低TMTV和TLG提示更可能获得客观缓解。
  • 骨髓代谢升高(BLR)提示生存较差,可能与调节性T细胞相关免疫抑制有关。

局限性

  • 回顾性研究,样本量55例。
  • 生物标志物以中位数二分,阈值需外部验证。
  • 结论需进一步评估以用于临床。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: An imaging-based stratification tool is needed to identify melanoma patients who will benefit from anti Programmed Death-1 antibody (anti-PD1). We aimed at identifying biomarkers for survival and response evaluated in lymphoid tissue metabolism in spleen and bone marrow before initiation of therapy. METHODS: This retrospective study included 55 patients from two institutions who underwent 18F-FDG PET/CT before anti-PD1. Parameters extracted were SUVmax, SUVmean, HISUV (SUV-based Heterogeneity Index), TMTV (total metabolic tumor volume), TLG (total lesion glycolysis), BLR (Bone marrow-to-Liver SUVmax ratio), and SLR (Spleen-to-Liver SUVmax ratio). Each parameter was dichotomized using the median as a threshold. Association with survival, best overall response (BOR), and transcriptomic analyses (NanoString assay) were evaluated using Cox prediction models, Wilcoxon tests, and Spearman's correlation, respectively. RESULTS: At 20.7 months median follow-up, 33 patients had responded, and 29 patients died. Median PFS and OS were 11.4 (95%CI 2.7-20.2) and 28.5 (95%CI 13.4-43.8) months. TMTV (>25cm3), SLR (>0.77), and BLR (>0.79) correlated with shorter survival. High TMTV (>25 cm3), SLR (>0.77), and BLR (>0.79) correlated with shorter survival, with TMTV (HR PFS 2.2, p = 0.02, and HR OS 2.5, p = 0.02) and BLR (HR OS 2.3, p = 0.04) remaining significant in a multivariable analysis. Low TMTV and TLG correlated with BOR (p = 0.03). Increased glucose metabolism in bone marrow (BLR) was associated with transcriptomic profiles including regulatory T cell markers (p < 0.05). CONCLUSION: Low tumor burden correlates with survival and objective response while hematopoietic tissue metabolism correlates inversely with survival. These biomarkers should be further evaluated for potential clinical application.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Seban RD, Nemer JS, Marabelle A, et al. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. Eur J Nucl Med Mol Imaging. 2019. PMID: 31346755. doi:10.1007/s00259-019-04411-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。